Pain Management Market Report 2026

The pain management market size has grown steadily in recent years. It will grow from $77.3 billion in 2025 to $80.93 billion in 2026 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to high prevalence of chronic pain conditions, widespread use of opioid-based medications, growing aging population, increasing surgical procedures, rising awareness of pain management therapies.

The pain management market size is expected to see steady growth in the next few years. It will grow to $96 billion in 2030 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to development of targeted and personalized pain therapies, growth in interventional pain management procedures, rising adoption of non-pharmacological treatments, increasing research and clinical trials in pain therapeutics, expanding access to pain management services. Major trends in the forecast period include growing preference for multimodal pain management approaches, rising use of non-opioid and opioid-sparing therapies, increasing adoption of minimally invasive interventional procedures, expansion of alternative and complementary pain therapies, greater focus on chronic pain and long-term pain management.

The increasing prevalence of chronic pain conditions is anticipated to drive the growth of the pain management market in the coming years. Chronic pain, defined as pain that persists for three months or longer, places a considerable burden on individuals by limiting daily activities and reducing overall quality of life. The rise in chronic pain cases is mainly attributed to factors such as aging populations, obesity, and musculoskeletal disorders, which contribute to conditions including arthritis, back pain, and joint-related issues. Pain management solutions address these needs by offering targeted therapies that alleviate discomfort, enhance mobility, and support improved daily functioning. For instance, in May 2023, according to the National Institutes of Health (NIH), a US-based organization, approximately 21% of adults in the United States reported experiencing chronic pain, while 8% suffered from high-impact chronic pain that restricted life or work activities. Therefore, the rising prevalence of chronic pain is fueling the growth of the pain management market.

Major companies operating in the pain management market are concentrating on the development of advanced drug formulations, such as transdermal therapies, to improve targeted drug delivery, increase patient adherence, and minimize side effects. Transdermal drugs are medications administered through the skin using delivery systems such as patches, gels, or creams. For example, in February 2025, Aveva Drug Delivery Systems Inc., a US-based transdermal drug delivery company, introduced a generic fentanyl transdermal patch, a prescription three-day patch designed for the management of moderate to severe chronic pain. This product provides continuous pain relief by steadily releasing fentanyl, a potent opioid analgesic, through the skin into the bloodstream over an extended period. It also features a comfortable and durable adhesive to ensure secure placement, along with a tamper-evident design to encourage safe and responsible use.

In October 2024, Stryker Corporation, a US-based medical technology company, acquired Vertos Medical Inc. for an undisclosed amount. Through this acquisition, Stryker aims to expand its non-surgical treatment portfolio and strengthen its presence in ambulatory surgery centers by incorporating the minimally invasive mild procedure, enhancing its capabilities in chronic pain care. Vertos Medical Inc. is a US-based medical device company focused on developing minimally invasive solutions for the management of chronic pain.

Major companies operating in the pain management market are Pfizer Inc., Johnson & Johnson, Merck & Co Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Medtronic plc, Eli Lilly and Company, Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Regeneron Pharmaceuticals Inc., Baxter International Inc., Mallinckrodt Pharmaceuticals plc, Purdue Pharma L.P., Nevro Corp.

North America was the largest region in the pain management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pain management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pain management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the pain management market by increasing costs associated with imported pharmaceuticals, medical devices, and interventional equipment used in pain therapies. Drug segments such as narcotics, anticonvulsants, and advanced medical devices are most affected, particularly in regions like North America and Asia-Pacific that rely on global supply chains. These cost pressures can influence treatment affordability and availability. However, tariffs have also encouraged domestic manufacturing, localized drug production, and increased investment in regional research and development capabilities.

The pain management market research report is one of a series of new reports that provides pain management market statistics, including pain management industry global market size, regional shares, competitors with a pain management market share, detailed pain management market segments, market trends and opportunities, and any further data you may need to thrive in the pain management industry. This pain management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pain management is a medical specialty dedicated to the assessment, treatment, and prevention of pain in order to enhance a patient’s quality of life. It incorporates a wide range of methods and therapies to manage both acute and chronic pain. The primary objective of pain management is to reduce suffering, restore functional ability, and improve overall well-being.

The main treatment types in pain management include medication, physical therapy, and alternative therapies. Medications are pharmaceutical agents used to alleviate pain of varying intensity, from mild to severe. These include several drug categories such as non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, sedatives, narcotics, antimigraine agents, antidepressants, and other types. The modes of purchase include over-the-counter and prescription-based options, and these treatments are used for a variety of indications, including neuropathic pain, cancer pain, facial pain and migraine, musculoskeletal pain, fibromyalgia, chronic back pain, joint pain, headache, and postoperative pain. The key end users include hospitals and clinics, pharmaceutical companies, medical device companies, research institutions, academic institutions, and others.

The pain management market includes revenues earned by entities through medication management, rehabilitation and psychological counseling, and interventional procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.